This was achieved by selective degradation of BCL-XL and inhibition of MCL-1 expression in tumor cells with DT2216 and AZD8055, respectively, therefore reducing on-target toxicity to platelets and other normal cells. The gene discussed is MCL1; the disease is neoplasm.